✦ LIBER ✦

M1 muscarinic agonists: Their potential in treatment and as disease-modifying agents in Alzheimer's disease

✍ Scribed by Abraham Fisher

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 108 KB
Volume: 50
Category: Article
ISSN: 0272-4391
DOI: 10.1002/1098-2299(200007/08)50:3/4<291::aid-ddr12>3.0.co;2-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of M1 subtype selective musc

Development of M1 subtype selective muscarinic agonists for Alzheimer's disease: Translation of in vitro selectivity into in vivo efficacy

✍ R.D. Schwarz; M.J. Callahan; R.E. Davis; J.C. Jaen; H. Tecle 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

Clinical trials in Alzheimer's disease (AD) with first generation muscarinic agonists (e.g., arecoline, oxotremorine, pilocarpine) produced inconsistent results due to poor pharmacokinetic properties and a lack of separation between central and peripheral activities observed with these compounds. Se

Autoradiographic distribution of M1, M2,

Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease

✍ Rafael Rodríguez-Puertas; Julio Pascual; Teresa Vilaró; Ángel Pazos 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 1 views

We studied the autoradiographic densities of all pharmacologically characterised muscarinic receptors (MR) in frontal, temporal, and visual cortex, hippocampal formation, and striatum in autopsied brains from 19 histopathologically verified patients of Alzheimer's disease (AD) and in matched control

The selective muscarinic M1 agonist AF10

The selective muscarinic M1 agonist AF102B decreases levels of total Aβ in cerebrospinal fluid of patients with Alzheimer's disease

✍ Roger M. Nitsch; Meihua Deng; Marsha Tennis; David Schoenfeld; John H. Growdon 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views